Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Developmental pluripotency-associated protein 3 (DPPA3) is a maternally expressed protein highly enriched in germ cells, pre-implantation embryos, and embryonic stem cells. It plays a critical role in epigenetic regulation, especially safeguarding DNA methylation landscapes in zygotes and oocytes, both by inhibiting maintenance DNA methylation and by modulating the interaction and subcellular localization of proteins like UHRF1 and DNMT1. DPPA3 is necessary for normal early embryonic development and maintenance of pluripotency, acting as a marker gene for naïve pluripotent stem cells. It is not a classic therapeutic target, but perturbations of DPPA3 or its pathways disrupt the stability of key pluripotency proteins (e.g., Nanog), leading to abnormal embryonic development and altered epigenetic programming.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Developmental pluripotency-associated protein 3 (DPPA3).